1. Home
  2. IMMP vs VACH Comparison

IMMP vs VACH Comparison

Compare IMMP & VACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • VACH
  • Stock Information
  • Founded
  • IMMP 1987
  • VACH 2023
  • Country
  • IMMP Australia
  • VACH United States
  • Employees
  • IMMP N/A
  • VACH N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • VACH
  • Sector
  • IMMP Health Care
  • VACH
  • Exchange
  • IMMP Nasdaq
  • VACH NYSE
  • Market Cap
  • IMMP 264.7M
  • VACH 274.7M
  • IPO Year
  • IMMP N/A
  • VACH 2024
  • Fundamental
  • Price
  • IMMP $2.05
  • VACH $10.03
  • Analyst Decision
  • IMMP Buy
  • VACH
  • Analyst Count
  • IMMP 2
  • VACH 0
  • Target Price
  • IMMP $8.50
  • VACH N/A
  • AVG Volume (30 Days)
  • IMMP 106.2K
  • VACH 7.9K
  • Earning Date
  • IMMP 11-26-2024
  • VACH 01-01-0001
  • Dividend Yield
  • IMMP N/A
  • VACH N/A
  • EPS Growth
  • IMMP N/A
  • VACH N/A
  • EPS
  • IMMP N/A
  • VACH N/A
  • Revenue
  • IMMP $2,563,302.00
  • VACH N/A
  • Revenue This Year
  • IMMP N/A
  • VACH N/A
  • Revenue Next Year
  • IMMP $10.84
  • VACH N/A
  • P/E Ratio
  • IMMP N/A
  • VACH N/A
  • Revenue Growth
  • IMMP 9.59
  • VACH N/A
  • 52 Week Low
  • IMMP $1.58
  • VACH $9.97
  • 52 Week High
  • IMMP $3.34
  • VACH $10.10
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 55.82
  • VACH N/A
  • Support Level
  • IMMP $1.85
  • VACH N/A
  • Resistance Level
  • IMMP $2.06
  • VACH N/A
  • Average True Range (ATR)
  • IMMP 0.10
  • VACH 0.00
  • MACD
  • IMMP 0.03
  • VACH 0.00
  • Stochastic Oscillator
  • IMMP 70.89
  • VACH 0.00

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

About VACH VOYAGER ACQUISITION CORP.

Voyager Acquisition Corp is a blank check company.

Share on Social Networks: